SGLT2 Inhibitors and Cardiovascular Risk Reduction

If we're treating hyperglycemia, where do we go? GLP1 receptor agonist at SGLT2 inhibitors have been shown to be beneficial. By the way, regardless of glucose control and regardless of whether the individual is on metformin or not. And then how about anything we should think of with regard to cardiovascular risk reduction if someone has diabetes and CVD? Well, two things. One, SGLT 2 having a role in the presence of albium inuria and finarinone as well in the Presence of Albium Inuria reducing both cardiovascular risk and progression of CVD.